ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2020-02-12 07:27 (494 d 04:55 ago) – Posting: # 21162
Views: 4,088

Hi MS,

» Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;


Ermmm...... WHAT???? :-D:party:

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,530 posts in 4,499 threads, 1,523 registered users;
online 17 (0 registered, 17 guests [including 2 identified bots]).
Forum time: Sunday 12:23 UTC (Europe/Vienna)

Intellect distinguishes between the possible and the impossible;
reason distinguishes between the sensible and the senseless.
Even the possible can be senseless.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5